Need Support?
Missing or Invalid DEX Z-Code Identifiers
PLA and Unlisted Code Mismatches
Tier 2 and Panel Stacking Violations
Prior Authorization Gaps on High-Cost Panels
Diagnosis-to-Test Linkage Failures
Single-gene and multi-gene solid tumor panels (EGFR 81235, KRAS 81275, BRAF 81210, ALK rearrangement testing), myeloid and lymphoid mutation panels, comprehensive genomic profiling panels, measurable residual disease (MRD) assays, and companion diagnostic testing tied to targeted therapy selection.
Comprehensive genomic profiling panels are billed under a single PLA or unlisted code that already reflects every analyte in the panel; billing individual gene components on top of the panel code is a stacking violation and a top MolDX audit trigger.
BRCA1/BRCA2 full gene sequence analysis (81162), Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2), multi-gene hereditary cancer panels (81432, 81433), PALB2, APC, and other high- and moderate-penetrance cancer susceptibility genes.
Diagnostic testing and unaffected at-risk family member testing require different ICD-10 code families under most payer policies; using a personal-history diagnosis code for a predisposition test on an unaffected relative is one of the most common denial triggers in this category.
CYP2D6, CYP2C19, CYP2C9, VKORC1, and SLCO1B1 single-gene assays, plus multi-gene PGx panels used to guide psychiatric medication selection, cardiovascular drug dosing, and pain management prescribing.
Medicare LCDs limit PGx coverage to specific drug classes and documented diagnosis linkage, and many commercial payers still classify broad multi-gene PGx panels as investigational; predetermination before testing prevents an avoidable 100% denial.
Hereditary cardiovascular disease panels (81439), hereditary neurological disorder panels (81448), exome sequencing (81415, 81416), genome sequencing (81425, 81426), and mitochondrial genome analysis (81440, 81441).
Genomic Sequencing Procedure codes already bundle the full multi-gene analysis into one code; billing separate Tier 1 codes for genes already captured inside that panel is unbundling and is routinely recouped on post-payment review.
Respiratory pathogen PCR panels, gastrointestinal pathogen panels, STI NAAT testing (chlamydia/gonorrhea 87491/87591), HCV and HIV viral load quantification (87522, 87536), and C. difficile toxin gene PCR (87493).
Syndromic panel codes already bundle multiple individual targets; billing separate target-specific codes alongside the panel code is one of the most frequently cited findings in molecular infectious disease post-payment audits.
Non-invasive prenatal testing (NIPT, 81420), expanded carrier screening panels, fragile X testing (81243, 81244), and chromosomal microarray for prenatal indications.
Coverage for NIPT and expanded carrier panels hinges on documented risk factors such as maternal age or family history; billing without that documentation attached is a leading cause of denial in reproductive genetic testing.
Chromosomal microarray for constitutional and oncology indications, FISH probe studies (88271–88275), and conventional chromosome analysis and karyotyping (88230–88264).
Technical and professional component splits for cytogenetic interpretation are frequently miscoded, and FISH billing must reflect the exact number of probes hybridized rather than the panel's marketed name.
Lab-specific and manufacturer-specific assays, including many multi-analyte NGS oncology panels, multi-gene PGx panels, and MRD assays that have been assigned their own dedicated PLA code by the AMA.
A PLA code applies only to the exact test version it was issued for; billing it without the matching DEX Z-Code identifier, or for a modified assay, is one of the most common MolDX-driven rejections we see.
TransLabs’ specialized RCM services are built exclusively for labs, addressing the unique challenges that generalist billers miss. We provide end-to-end revenue cycle solutions designed specifically to turn laboratory complexity into profitability.
Complete payer enrollment, CLIA certification management, and network participation setup across all insurance carriers. TransLabs manages every credentialing detail so that your laboratory gets paid in-network from day one without any administrative delays.
Real-time insurance verification, benefits investigation, and prior auth completed before specimen processing begins. Confirming coverage upfront eliminates preventable denials and protects your lab from unexpected reimbursement failures.
Patient registration, appointment coordination, insurance verification, and customer service excellence managed by experienced laboratory billing professionals. A well-run front office reduces downstream billing errors and creates a better experience.
TransLabs provides expert RCM services to clinical laboratories in all 50 states, delivering the same exceptional results whether you’re a community hospital lab or a large reference facility. We bring specialized lab billing expertise to facilities nationwide, combining remote efficiency with hands-on partnership.
Palmetto GBA's MolDX Program requires a unique DEX Z-Code identifier on every in-scope molecular diagnostic claim, reported alongside the CPT or PLA code. TransLabs registers and maintains your lab's Z-Codes in the DEX Diagnostics Exchange and validates the correct identifier against every claim before it's submitted, not just for the tests you run most often.
Each Medicare Administrative Contractor maintains its own LCDs specifying which diagnoses support coverage for specific molecular and genetic tests, and these policies frequently distinguish diagnostic testing from screening or predisposition testing. TransLabs maintains live LCD databases by MAC and validates ICD-10 linkage before submission.
CMS and commercial payers actively monitor for inappropriate stacking of Tier 2 and unlisted molecular pathology codes, and for PLA codes billed without their required identifiers. TransLabs cross-references every claim against current AMA PLA code releases and CMS stacking guidance before it leaves our system.
High-cost NGS panels, hereditary cancer testing, and expanded carrier screens frequently require prior authorization or detailed medical necessity documentation before specimen collection. TransLabs builds these checks into your front-end intake workflow so authorization is confirmed before testing begins, not after a denial arrives.
Labs meeting the applicable laboratory definition under the Protecting Access to Medicare Act carry mandatory private payer data reporting obligations during designated collection periods, and molecular and genomic tests are frequently subject to this reporting. TransLabs tracks your lab's PAMA obligations throughout the year.
Genetic and molecular testing has drawn sustained attention from CMS and the Office of Inspector General in recent years, including enforcement actions tied to medically unnecessary panels and improper billing arrangements. TransLabs builds compliance protocols around current program integrity priorities so your lab's billing patterns hold up under scrutiny.
Most billing companies treat molecular diagnostics as an add-on to chemistry or pathology billing. It isn’t. Molecular and genomic testing has its own code families, Z-Code and PLA governance, and prior authorization landscape. TransLabs built a dedicated molecular team; coders and appeal writers who work exclusively in molecular claims, not generalists handling a mixed caseload.
Dedicated molecular billing specialist assigned to your lab
Complimentary 12-month claims audit across Medicare, Medicaid, and commercial payers
Uncover your top 3 revenue leaks (Z-Code gaps, stacking errors, prior auth denials)
Custom strategy tailored to your test menu and LIS/genomics platform
Live in 24 hours with no contracts and no upfront fees
Pay only a percentage of what we collect for you